ChemoMetec Full Year 2024 Earnings: EPS Beats Expectations

ChemoMetec (CPH:CHEMM) Full Year 2024 Results

Key Financial Results

• Revenue: kr.407.9m (down 8.2% from FY 2023).
• Net income: kr.136.3m (down 24% from FY 2023).
• Profit margin: 33% (down from 40% in FY 2023). The decrease in margin was primarily driven by lower revenue.
• EPS: kr.7.83 (down from kr.10.27 in FY 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

ChemoMetec EPS Beats Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 5.5%.

Looking ahead, revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.

Performance of the market in Denmark.

The company's shares are up 14% from a week ago.

Risk Analysis

It is worth noting though that we have found 2 warning signs for ChemoMetec (1 doesn't sit too well with us!) that you need to take into consideration.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.